Topsun And Bayer Delay Record Deal On Black And White Cold Medicine
This article was originally published in PharmAsia News
Topsun Science and Technology has signed a supplementary agreement with Bayer to extend the transaction period for the latter to acquire Topsun's popular Black and White cold medicine. The new deadline for completing the deal is now postponed to June 30, 2008, eight months beyond the original contract. The supplementary agreement maintains the original transaction price but adds several new conditions for both parties. If the high-profile deal goes through, Black and White will break the acquisition record in China's drug industry with its price of 1.07 billion yuan. (Click here for more - Chinese Language)
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.